Condition: Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma · Sponsor: New York Medical College
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
This description comes directly from the study's public registry record.
Mitchell Cairo, MD · 914-594-2150 · Mitchell_Cairo@nymc.edu
Jessica Hochberg, MD · 914-594-2150 · jessica_hochberg@nymc.edu
Always discuss trial participation with your own doctor first.
| New York Medical College | Valhalla, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02393157